# UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia

> **NCT07530380** · EARLY_PHASE1 · RECRUITING · sponsor: **The Second Hospital of Anhui Medical University** · enrollment: 15 (estimated)

## Conditions studied

- AIHA - Warm Autoimmune Hemolytic Anemia
- UCART

## Interventions

- **BIOLOGICAL:** QT-219C Cell Injection

## Key facts

- **NCT ID:** NCT07530380
- **Lead sponsor:** The Second Hospital of Anhui Medical University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2029-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07530380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07530380, "UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07530380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*